HCW Biologics announces data presented for TCE Program based on TRBC platform

HCW Biologics (HCWB) announced the data presented for their tetra-valent, second-generation T-Cell Engager, TCE, Program based on their novel TRBC platform technology, at the SITC 40th Annual Meeting, taking place from November 5 to 9, 2025 in National Harbor, Maryland. Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer, stated, “Remarkably, our preclinical studies showed that HCW11-018b, our lead second-generation TCE product candidate, could shrink the well-established tumors in xenograft animal models including the PDX model. There was 100% survival among tumor-bearing mice treated with HCW11-018b, whereas none of the untreated mice survived. In addition to enhancing the healthspan for patients suffering from a wide spectrum of solid tumors, especially pancreatic cancer and glioblastoma, we believe our approach could expand the number of indications that could possibly be treated with our tetra-valent, second-generation TCEs, such as autoimmune diseases and quality-of-life conditions.”